Trial Information
Current as of February 19, 2025
Active, not recruiting
Keywords
ClinConnect Summary
Left main coronary artery (LMCA) is a major branch of coronary artery and supplies a large bulk of myocardium.
Revascularization by either surgical coronary bypass grafting (CABG) or percutaneous coronary intervention (PCI) is recommended for significant unprotected LMCA disease, with CABG being preferred if there is significant involvement in other coronary arteries1,2. CABG has been demonstrated to confer survival benefit over medical therapies patients with LMCA in earlier clinical trials3,4,5. However, these trials were performed before the wide adoption of modern medical therapies suc...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with significant LMCA disease who were on the waitlist for CABG since 1st January 2000 to 31st December 2020.
- • The decision for CABG over PCI as a mode of revascularization for the patients on this waitlist were collectively made by the HEART team
- Exclusion Criteria:
- • patients with co-existing significant valvular heart disease requiring concomitant surgical intervention, and unstable patients in whom urgent surgical intervention was performed
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, Shatin, Hong Kong
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
